著者
吉田 真平 藤田 真敬 大塚 康民 柳田 保雄 柏崎 利昌 田村 敦 別宮 愼也 森本 浩吉
出版者
航空医学実験隊
雑誌
航空医学実験隊報告 (ISSN:00232858)
巻号頁・発行日
vol.58, no.3, pp.27-40, 2018 (Released:2018-11-27)
参考文献数
75

In Japan, “hay fever”, seasonal allergic rhinitis caused by pollen, has become more popular and has been called national affliction. Although there are less serious symptoms of hay fever, symptoms including sneezing, runny nose and itchy eye, sleep impairment, fatigue, impairment of learning and cognitive performance, have potential safety risks for flying or driving. The usage of some medications such as anti-histamines with less adverse effects on central nervous system, are approved for pilots under an appropriate regulation. However, the criteria of approval and conditions in the regulations differs from organizations in countries. In this article, we summarize current medications for “hay fever” including antihistamines, montelukast, subcutaneous and sublingual immunotherapy. We also compare aeromedical regulations for these medications between Japan and U.S.. The immunotherapy, minimizing allergic reaction for “hay fever”, may be one of the potential option for pilots.

言及状況

外部データベース (DOI)

Twitter (10 users, 10 posts, 41 favorites)

<参考文献> https://t.co/nH9SI066mv https://t.co/IPl5GwmXSA https://t.co/ix4XTrCEz2 https://t.co/naoseF1RH8 https://t.co/mVSkxpdEGu https://t.co/ibYOSoFuU4 https://t.co/zbtk6da4o0 https://t.co/DqeYZ5JrXv https://t.co/BrCeFVY3YU
フェキソフェナジン、ロラタジンは日米ともにパイロットの内服直後の飛行が認められているが、管轄する組織により細部基準が異なる。 【航空医学実験隊報告】 パイロットの花粉症治療における規制 https://t.co/y7JzDGTwzu

収集済み URL リスト